SecBot SecBot
PRESS-RELEASE ·Filed Jul 17, 2026

EVAX

Evaxion
NEUTRAL
Impact 4/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

The ESMO presentation is a binary catalyst for October 2026. The stand-alone efficacy data will be critical for partnership discussions. Monitor for any pre-ESMO abstract or partnership announcement.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.08
T+0 close · Jul 17, 2026 · via day close
Latest settled
−2.44%
T+60 · $3.00
Vs SPY
−7.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 17 $3.08entry
  2. T+1 · 4mo ago −4.39%α −4.23% · $2.94
  3. T+5 · 4mo ago −0.81%α −0.13% · $3.05
  4. T+20 · 3mo ago +8.62%α +4.17% · $3.34
  5. T+60 · 5w ago −2.44%α −7.12% · $3.00
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion will present three-year Phase 2 data for personalized cancer vaccine EVX-01 at ESMO 2026 (Oct 23-27). The third-year data includes a stand-alone therapy cohort, offering insight into EVX-01's effect without anti-PD-1 combination. Prior two-year data showed a 75% ORR and durable responses, but the stock has historically declined on prior neutral reports, suggesting limited market enthusiasm for early-stage data milestones.

Key Facts

  • Three-year Phase 2 data for EVX-01 will be presented at ESMO Congress 2026 (Oct 23-27, Madrid).
  • Third-year data includes a subset of patients receiving EVX-01 as stand-alone therapy (no anti-PD-1 combination).
  • Prior two-year data showed 75% ORR (12/16 patients), 92% durable response at 2 years, and no relapses.
  • EVX-01 induced immune response in all patients; 86% of targeted neoantigens generated T-cell responses.

Financial Impact

No financial data provided; clinical-stage company with no revenue.

Risk Factors

  • Three-year data may not show incremental benefit over two-year data.
  • Stand-alone therapy cohort may have limited sample size, reducing statistical significance.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3329028

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 17, 2026